Figure 1.
RFS following HCT in patients with FLT3+AML randomized to receive sorafenib or placebo.

RFS following HCT in patients with FLT3+AML randomized to receive sorafenib or placebo.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal